Effect and Tolerability of Lactobacillus Rhamnosus GG LA801 for the Preventive Nutritional Care of Nosocomial Diarrhea in Children

NATerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 29, 2019

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions
Nosocomial InfectionDiarrhea, Infantile
Interventions
DIETARY_SUPPLEMENT

Babybiane Imedia or placebo

Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.

Trial Locations (2)

Unknown

Centre hospitalier d'Auxerre, Auxerre

Hopital Robert Debré, Paris

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Clinact

OTHER

collaborator

Clinfile

INDUSTRY

lead

PiLeJe

INDUSTRY

NCT04628819 - Effect and Tolerability of Lactobacillus Rhamnosus GG LA801 for the Preventive Nutritional Care of Nosocomial Diarrhea in Children | Biotech Hunter | Biotech Hunter